Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome

Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment... Coronary Heart Disease Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome Kai C. Wollert, MD; Tibor Kempf, MD; Bo Lagerqvist, MD, PhD; Bertil Lindahl, MD, PhD; Sylvia Olofsson, BSc; Tim Allhoff, BSc; Timo Peter, BSc; Agneta Siegbahn, MD, PhD; Per Venge, MD, PhD; Helmut Drexler, MD; Lars Wallentin, MD, PhD Background—An invasive treatment strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results—The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Circulation Wolters Kluwer Health

Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome

Wallentin, Lars
Circulation , Volume 116 (14) – Oct 1, 2007
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/growth-differentiation-factor-15-for-risk-stratification-and-selection-mXizN0O08S

References (26)

ISSN
0009-7322
eISSN
1524-4539
DOI
10.1161/CIRCULATIONAHA.107.697714
pmid
17848615
Publisher site
See Article on Publisher Site

Abstract

Coronary Heart Disease Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non–ST-Elevation Acute Coronary Syndrome Kai C. Wollert, MD; Tibor Kempf, MD; Bo Lagerqvist, MD, PhD; Bertil Lindahl, MD, PhD; Sylvia Olofsson, BSc; Tim Allhoff, BSc; Timo Peter, BSc; Agneta Siegbahn, MD, PhD; Per Venge, MD, PhD; Helmut Drexler, MD; Lars Wallentin, MD, PhD Background—An invasive treatment strategy improves outcome in patients with non–ST-elevation acute coronary syndrome at moderate to high risk. We hypothesized that the circulating level of growth differentiation factor 15 (GDF-15) may improve risk stratification. Methods and Results—The Fast Revascularization during InStability in Coronary artery disease II (FRISC-II) trial randomized patients with non–ST-elevation acute coronary syndrome to an invasive or conservative strategy with a follow-up for 2 years. GDF-15 and other biomarkers were determined on admission in 2079 patients. GDF-15 was moderately elevated (between 1200 and 1800 ng/L) in 770 patients (37.0%), and highly elevated (1800 ng/L) in 493 patients (23.7%). Elevated levels of GDF-15 independently predicted the risk of the composite end point of death or recurrent myocardial infarction in the conservative group (P0.016) but not in the invasive group. A significant interaction existed between the GDF-15 level

Journal

Circulation – Wolters Kluwer Health

Published: Oct 1, 2007

There are no references for this article.